Quick Answer
Emergent BioSolutions Inc. reported Operating Income Loss of -$108.70 million for the year ending 2024.
- Emergent BioSolutions Inc. showed an increase of +85.0% in Operating Income Loss from 2023 to 2024.
- This data is from Emergent BioSolutions Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2025.
- XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$13.35 million | Q2 2013: $14.71 million | Q3 2013: $18.15 million | Q4 2013: $23.29 million | Q1 2014: -$25.46 million | Q2 2014: $7.86 million | Q3 2014: $31.03 million | Q4 2014: $44.62 million | Q1 2015: -$28.31 million | Q2 2015: $21.45 million | Q3 2015: $63.16 million | Q4 2015: $49.89 million | Q1 2016: $21.16 million | Q2 2016: -$2.04 million | Q3 2016: $35.48 million | Q1 2017: $14.91 million | Q2 2017: $8.53 million | Q3 2017: $47.77 million | Q1 2018: -$9.50 million | Q2 2018: $66.80 million | Q3 2018: $21.30 million | Q1 2019: -$27.40 million | Q2 2019: -$7.00 million | Q3 2019: $70.70 million | Q4 2019: $77.80 million | Q1 2020: -$11.60 million | Q2 2020: $126.00 million | Q3 2020: $61.30 million | Q4 2020: $258.10 million | Q1 2021: $95.40 million | Q2 2021: $14.50 million | Q3 2021: -$34.70 million | Q1 2022: $6.90 million | Q2 2022: -$76.30 million | Q3 2022: -$45.30 million | Q1 2023: -$147.60 million | Q2 2023: -$292.90 million | Q3 2023: -$242.10 million | Q1 2024: $39.80 million | Q2 2024: -$203.50 million | Q3 2024: $64.50 million | Q1 2025: $49.90 million | Q2 2025: $1.60 million | Q3 2025: $76.50 million.
- Over the full 16 years of available data (2009 to 2024), Emergent BioSolutions Inc.'s Operating Income Loss has declined by 370.7%.
- Historical annual values: Fiscal year 2024: -$108.70 million | Fiscal year 2023: -$726.40 million | Fiscal year 2022: -$170.00 million | Fiscal year 2021: $341.40 million | Fiscal year 2020: $433.80 million | Fiscal year 2019: $114.10 million | Fiscal year 2018: $89.80 million | Fiscal year 2017: $124.30 million | Fiscal year 2016: $105.50 million | Fiscal year 2015: $141.51 million | Fiscal year 2014: $89.19 million | Fiscal year 2013: $42.80 million | Fiscal year 2012: $29.97 million | Fiscal year 2011: $32.10 million | Fiscal year 2010: $73.56 million | Fiscal year 2009: $40.15 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: